Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice

Journal of Neurochemistry

Volumn 132, Issue 1, 2015, Pages 135-145

  Ittner, Arne ^a,b   Bertz, Josefine ^a,b   Suh, Lisa S ^a   Stevens, Claire H ^a   Götz, Jürgen ^b,c   Ittner, Lars M ^a,b,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Alzheimer's disease; passive immunization; phosphorylation; tau; tauopathy

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBOY PS 404; TAU PROTEIN; UNCLASSIFIED DRUG; ANTIBODY; PHF1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; FEMALE; HIPPOCAMPAL CA1 REGION; IMMUNOREACTIVITY; MALE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TAUOPATHY; ANIMAL; BRAIN CORTEX; C57BL MOUSE; CELL INCLUSION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROCEDURES; TAUOPATHIES; TRANSGENIC MOUSE;

MUS; MUS MUSCULUS;

ANIMALS; ANTIBODIES; CA1 REGION, HIPPOCAMPAL; CEREBRAL CORTEX; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; INCLUSION BODIES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES; TRANSCRIPTION FACTORS;

EID: 84923626096     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12821     Document Type: Article

References (38)

1. d'Abramo C., Acker C. M., Jimenez H. T., and, Davies P., (2013) Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS ONE 8, e62402.
2. Allen B., Ingram E., Takao M., et al,. (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22, 9340-9351.
3. Asuni A. A., Boutajangout A., Quartermain D., and, Sigurdsson E. M., (2007) Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J. Neurosci. 27, 9115-9129.
4. Bi M., Ittner A., Ke Y. D., Gotz J., and, Ittner L. M., (2011) Tau-targeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS ONE 6, e26860.
5. Boutajangout A., Ingadottir J., Davies P., and, Sigurdsson E. M., (2011) Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J. Neurochem. 118, 658-667.
6. Braak H., and, Braak E., (1995) Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol. Aging, 16, 271-278; discussion 278-284.
7. Castillo-Carranza D. L., Sengupta U., Guerrero-Munoz M. J., et al,. (2014) Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J. Neurosci. 34, 4260-4272.
8. Chai X., Wu S., Murray T. K., et al,. (2011) Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J. Biol. Chem. 286, 34457-34467.
9. Goedert M., Spillantini M. G., Jakes R., Crowther R. A., Vanmechelen E., Probst A., Gotz J., Burki K., and, Cohen P., (1995) Molecular dissection of the paired helical filament. Neurobiol. Aging 16, 325-334.
10. Gotz J., and, Ittner L. M., (2008) Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 9, 532-544.
11. Gotz J., Chen F., Barmettler R., and, Nitsch R. M., (2001a) Tau filament formation in transgenic mice expressing P301L tau. J. Biol. Chem. 276, 529-534.
12. Gotz J., Chen F., van Dorpe J., and, Nitsch R. M., (2001b) Formation of neurofibrillary tangles in P301 l tau transgenic mice induced by Abeta 42 fibrils. Science 293, 1491-1495.
13. Gotz J., Ittner A., and, Ittner L. M., (2012) Tau-targeted treatment strategies in Alzheimer's disease. Br. J. Pharmacol. 165, 1246-1259.
14. Greenberg S. G., Davies P., Schein J. D., and, Binder L. I., (1992) Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 267, 564-569.
15. Grueninger F., Bohrmann B., Czech C., Ballard T. M., Frey J. R., Weidensteiner C., von Kienlin M., and, Ozmen L., (2010) Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol. Dis. 37, 294-306.
16. Gu J., Congdon E. E., and, Sigurdsson E. M., (2013) Two novel tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce tau pathology. J. Biol. Chem., 288, 33081-33095.
17. Haass C., and, Selkoe D. J., (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
18. Ittner L. M., and, Gotz J., (2011) Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 12, 65-72.
19. Ittner L. M., Fath T., Ke Y. D., Bi M., van Eersel J., Li K. M., Gunning P., and, Gotz J., (2008) Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl Acad. Sci. USA 105, 15997-16002.
20. Ittner L. M., Ke Y. D., and, Gotz J., (2009) Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 284, 20909-20916.
21. Ittner A., Ke Y. D., van Eersel J., Gladbach A., Gotz J., and, Ittner L. M., (2011) Brief update on different roles of tau in neurodegeneration. IUBMB Life 63, 495-502.
22. Ittner A., Block H., Reichel C. A., et al,. (2012) Regulation of PTEN activity by p38delta-PKD1 signaling in neutrophils confers inflammatory responses in the lung. J. Exp. Med. 209, 2229-2246.
23. Ittner A. A., Bertz J., Chan T. Y., van Eersel J., Polly P., and, Ittner L. M., (2014) The nucleotide exchange factor SIL1 is required for glucose-stimulated insulin secretion from mouse pancreatic beta cells in vivo. Diabetologia, 57, 1410-1419.
24. Jeganathan S., Hascher A., Chinnathambi S., Biernat J., Mandelkow E. M., and, Mandelkow E., (2008) Proline-directed pseudo-phosphorylation at AT8 and PHF1 epitopes induces a compaction of the paperclip folding of Tau and generates a pathological (MC-1) conformation. J. Biol. Chem. 283, 32066-32076.
25. Jicha G. A., (2009) Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'? Expert. Opin. Biol. Ther. 9, 481-491.
26. Matenia D., and, Mandelkow E. M., (2009) The tau of MARK: a polarized view of the cytoskeleton. Trends Biochem. Sci. 34, 332-342.
27. Nimmerjahn F., Bruhns P., Horiuchi K., and, Ravetch J. V., (2005) FcgammaRIV: a novel FcR with distinct IgG subclass specificity. Immunity 23, 41-51.
28. Noble W., Hanger D. P., Miller C. C., and, Lovestone S., (2013) The importance of tau phosphorylation for neurodegenerative diseases. Front. Neurol. 4, 83.
29. Rosenmann H., (2013) Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies. Curr. Alzheimer Res. 10, 217-228.
30. Rosenmann H., Grigoriadis N., Karussis D., Boimel M., Touloumi O., Ovadia H., and, Abramsky O., (2006) Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch. Neurol. 63, 1459-1467.
31. Rozenstein-Tsalkovich L., Grigoriadis N., Lourbopoulos A., Nousiopoulou E., Kassis I., Abramsky O., Karussis D., and, Rosenmann H., (2013) Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp. Neurol. 248, 451-456.
32. Seubert P., Mawal-Dewan M., Barbour R., et al,. (1995) Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J. Biol. Chem. 270, 18917-18922.
33. Southwell A. L., and, Patterson P. H., (2010) Antibody therapy in neurodegenerative disease. Rev. Neurosci. 21, 273-287.
34. Takai T., (2002) Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2, 580-592.
35. Troquier L., Caillierez R., Burnouf S., et al,. (2012) Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr. Alzheimer Res. 9, 397-405.
36. Vigo-Pelfrey C., Seubert P., Barbour R., et al,. (1995) Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 45, 788-793.
37. Yanamandra K., Kfoury N., Jiang H., Mahan T. E., Ma S., Maloney S. E., Wozniak D. F., Diamond M. I., and, Holtzman D. M., (2013) Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron, 80, 402-414.
38. Zetterberg H., Wilson D., Andreasson U., Minthon L., Blennow K., Randall J., and, Hansson O., (2013) Plasma tau levels in Alzheimer's disease. Alzheimers Res. Ther. 5, 9.